Clinical Trial Update: Motixafortide for MRD Sensitization in AML [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of motixafortide for sensitizing measurable residual disease in acute myeloid leukemia is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Motixafortide (motixafortide)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Acute Myeloid Leukemia, Measurable Residual Disease | Phase 2 | Status: NOT_YET_RECRUITING